OPKO Health Inc OPK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
-
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
-
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
-
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
-
OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results
-
OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024
-
OPKO Health Announces $100 Million Share Repurchase Program
-
OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments
Trading Information
- Previous Close Price
- $1.48
- Day Range
- $1.47–1.54
- 52-Week Range
- $0.85–1.75
- Bid/Ask
- $1.49 / $1.50
- Market Cap
- $1.03 Bil
- Volume/Avg
- 2.6 Mil / 3.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 3,930
- Website
- https://www.opko.com
Comparables
Valuation
|
Metric
|
OPK
|
688468
|
688606
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.95 | 26.11 |
Price/Book Value | 0.74 | 1.75 | 1.24 |
Price/Sales | 1.50 | 5.25 | 6.19 |
Price/Cash Flow | — | 12.29 | 18.86 |
Price/Earnings
OPK
688468
688606
Financial Strength
|
Metric
|
OPK
|
688468
|
688606
|
|---|---|---|---|
Quick Ratio | 0.71 | 4.71 | 7.73 |
Current Ratio | 1.63 | 5.48 | 8.43 |
Interest Coverage | −9.91 | 111.54 | 235.62 |
Quick Ratio
OPK
688468
688606
Profitability
|
Metric
|
OPK
|
688468
|
688606
|
|---|---|---|---|
Return on Assets (Normalized) | −10.22% | 7.46% | 4.14% |
Return on Equity (Normalized) | −14.83% | 9.59% | 4.49% |
Return on Invested Capital (Normalized) | −10.92% | 7.98% | 3.52% |
Return on Assets
OPK
688468
688606
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Rvsxwxcmnk | Lsmh | $229.1 Bil | |||
| Danaher Corp
DHR
| Nzvqsfrbx | Sdmvzr | $193.5 Bil | |||
| IQVIA Holdings Inc
IQV
| Gmhfynv | Pqvwggh | $42.2 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Dvssqtxb | Kvmc | $41.0 Bil | |||
| Agilent Technologies Inc
A
| Zsbgtngw | Mhddn | $40.1 Bil | |||
| Mettler-Toledo International Inc
MTD
| Qttvjgjdf | Wmgsff | $30.1 Bil | |||
| Icon PLC
ICLR
| Gwhfrcbr | Gyswt | $23.5 Bil | |||
| Waters Corp
WAT
| Xghxqgqx | Jmqnb | $20.2 Bil | |||
| Illumina Inc
ILMN
| Dnjtmjsd | Ffznpc | $20.1 Bil | |||
| Labcorp Holdings Inc
LH
| Gxlmxnfjz | Pgzhwt | $18.4 Bil |
United States